(Alliance News) - Hutchmed (China) Ltd on Thursday said it has launched a study into the combined use of Fruquintinib and Tislelizumab on patients with advanced triple negative breast cancer or advanced endometrial cancer.
Hong-Kong based pharmaceutical company said the first patient was dosed on Tuesday in the Phase Ib/II trial, which is located in the US.
The tests aim to assess the safety and efficacy of Fruquintinib combined with Tislelizumab in patients with locally advanced or metastatic forms of the cancers, the company said.
Tislelizumab was developed by biotechnology firm BeiGene as a treatment for a broad range of both solid tumor and hematologic cancer. While Fruquintinib is used for the treatment of patients with metastatic colorectal cancer.
Shares in Hutchmed fell 2.3% to 547.00 pence each in London on Thursday morning.
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)